Desmopressin Dosing for Adults

For hemostatic indications (von Willebrand disease, mild-to-moderate hemophilia A), administer desmopressin 0.3 µg/kg IV diluted in 50 mL saline over 20–30 minutes; for central diabetes insipidus, start with 0.05 mg (50 µg) oral tablets twice daily and titrate to 0.1–0.8 mg/day in divided doses; for nocturia, use 50 µg oral disintegrating tablet at bedtime with strict fluid restriction.

Hemostatic Indications (von Willebrand Disease & Hemophilia A)

Intravenous Dosing

Administer 0.3 µg/kg body weight diluted in 50 mL saline infused over 20–30 minutes for patients with Type 1 von Willebrand disease or mild-to-moderate hemophilia A 1, 2, 3.
Peak effect occurs 30–60 minutes after infusion, raising factor VIII and von Willebrand factor levels 2–3-fold 1, 2.
Do not exceed three consecutive doses due to tachyphylaxis from depletion of endothelial storage pools; switch to factor concentrates if further hemostatic support is needed 1, 2.

Critical Contraindication

Never administer desmopressin to patients with Type 2B von Willebrand disease—it precipitates dangerous platelet aggregation, consumption, and thrombocytopenia 2, 3.
Accurate VWD subtyping with VWF antigen, VWF activity, and FVIII levels is mandatory before any desmopressin use 2.

Perioperative Hemostatic Dosing

For major surgery or neuraxial anesthesia in Type 1 VWD patients, give desmopressin 0.3 µg/kg IV 30–60 minutes before the procedure to achieve VWF and FVIII levels ≥50 IU/dL 2, 3.
Combine with tranexamic acid (oral rinse 10 mL of 5% solution four times daily or systemic administration) to enhance hemostasis, achieving >90% success rates 2, 3.
For minor procedures in Type 1 VWD, desmopressin ± tranexamic acid is usually sufficient 2, 3.

Hemophilia A Considerations

Desmopressin is effective only in mild-to-moderate hemophilia A (factor VIII >5% of normal); it does not work in severe hemophilia A due to absent FVIII stores 1.
Perform a trial dose before elective procedures to confirm a 2–3-fold rise in FVIII levels 1.
Desmopressin does not increase factor IX and is ineffective in hemophilia B 1.

Central Diabetes Insipidus

Oral Tablet Dosing

Start with 0.05 mg (50 µg) twice daily and titrate individually based on urine output and osmolality 4, 5.
Most patients require 0.1–0.8 mg/day in divided doses (two or three times daily) to achieve adequate antidiuresis 4, 5.
Maximum recommended dose is 1.2 mg/day divided into multiple doses 4.
Onset of action occurs at 1 hour, with maximum effect at 4–7 hours after oral administration 4, 5.

Dose Conversion from Intranasal to Oral

Oral tablets require 15–30 times higher doses than intranasal formulations due to lower bioavailability 5.
When switching from intranasal spray (typically 10–20 µg/day) to oral tablets, begin oral dosing 12–24 hours after the last intranasal dose 4, 5.
A patient on 10 µg intranasal spray typically requires 200–300 µg oral tablets daily 5.

Monitoring and Adjustment

Adjust each dose separately to establish an adequate diurnal rhythm of water turnover 4.
Monitor urine volume, urine osmolality, serum sodium, and plasma osmolality at baseline, 3–7 days after starting, and every 3–6 months 6.
Enforce fluid restriction: patients should limit intake to match urine output to prevent hyponatremia 4, 6.

Safety in Elderly Patients

In patients ≥65 years, do not exceed 0.2 mg/day to minimize hyponatremia risk 6.
Elderly patients have decreased renal clearance and are at higher risk for toxic reactions; close monitoring of serum sodium is essential 4, 6.
Hyponatremia incidence is approximately 4.4% in elderly patients on doses ≤0.2 mg/day, with full recovery after stopping medication 6.

Nocturia

Oral Disintegrating Tablet Dosing

Start with 50 µg at bedtime for men with nocturia (≥2 nocturnal voids) 7.
The 50 µg dose is the minimum effective dose, providing sustained improvement with a superior safety profile compared to 75 µg 7.
Response is typically seen within 1 week and sustained throughout treatment 7.
The 50 µg dose reduces nocturnal voids by approximately 0.37 episodes/night and increases time to first void by ~40 minutes 7.

Fluid Restriction

Limit fluid intake to a minimum from 1 hour before desmopressin administration until the next morning, or at least 8 hours after administration 4.
This restriction is critical to prevent water intoxication and hyponatremia 4, 8.

Safety Monitoring

Monitor serum sodium at baseline and periodically during treatment 7, 6.
Only 2 subjects (ages 74 and 79) on 50 µg developed serum sodium <130 mmol/L, compared to 9 subjects on 75 µg 7.
If serum sodium decreases below 130 mmol/L, stop desmopressin immediately 6.

Primary Nocturnal Enuresis (Pediatric Dosing Included for Context)

Oral Tablet Dosing for Children ≥6 Years

Start with 0.2 mg at bedtime and titrate up to 0.6 mg to achieve the desired response 4, 9.
Enforce strict fluid restriction from 1 hour before administration until the next morning (at least 8 hours) 4, 9.
Desmopressin reduces the mean number of wet nights by approximately 1.8 nights/week compared to placebo 9.

Duration of Effect

The antidiuretic effect lasts approximately 24 hours after a single dose 8.
With repeated dosing every 12 hours, the effect is sustained but tachyphylaxis can develop 8.

Key Safety Considerations Across All Indications

Hyponatremia Risk

Single doses (0.3 µg/kg IV or 300 µg intranasal) cause minimal serum sodium changes (median lowest sodium 140–141 mmol/L) 8.
Repeated doses (four doses at 12-hour intervals) can decrease serum sodium to 139 mmol/L and increase body weight by 1.3 kg due to water retention 8.
If desmopressin is repeated for up to 48 hours, restrict fluid intake to 2 liters/day in adults 8.

Tachyphylaxis

After three consecutive doses, endothelial storage pools are depleted and further desmopressin becomes ineffective 1, 2.
Switch to factor concentrates (for hemostatic indications) or allow a washout period before resuming desmopressin 1, 2.

Contraindications

Type 2B von Willebrand disease (absolute contraindication for hemostatic use) 2, 3.
Severe renal impairment (desmopressin is renally excreted) 4.
Hyponatremia or conditions predisposing to fluid overload 4.

Adverse Effects

Common: headache, dizziness, nasal discomfort (with intranasal formulations), gastrointestinal discomfort, mood changes 9.
Serious: hyponatremia, seizures (rare, associated with severe hyponatremia), thrombocytopenia (in Type 2B VWD if mistakenly given) 2, 9.

Route-Specific Considerations

Intravenous vs. Intranasal vs. Oral

Intravenous (0.3 µg/kg) and intranasal (300 µg) formulations produce equivalent antidiuretic effects lasting ~24 hours 8.
Oral tablets have lower bioavailability and require 15–30 times higher doses than intranasal formulations 5.
No difference in hyponatremia risk between nasal and oral routes when appropriately dosed 10.

Subcutaneous Administration

Desmopressin can also be given subcutaneously at 0.3 µg/kg for hemostatic indications, with similar pharmacodynamics to IV administration 1.

Clinical Pitfalls to Avoid

Never use desmopressin prophylactically in patients without documented von Willebrand disease, hemophilia, or platelet defects—meta-analyses show no benefit in cardiac surgery patients without bleeding disorders 3.
Do not rely on aPTT alone to guide hemostatic therapy; it may be prolonged with low factor VIII but does not reliably predict bleeding 1, 2.
Do not exceed three consecutive doses without switching to factor concentrates due to tachyphylaxis 1, 2.
Always enforce fluid restriction when treating nocturia or enuresis to prevent hyponatremia 4, 7, 8.
Confirm VWD subtype before any desmopressin use—giving desmopressin to Type 2B patients can be life-threatening 2, 3.

What are the recommended adult dosing regimens for desmopressin (DDAVP) for various indications?

Have a follow-up question?